Note 15 - Segments (Tables)

6 Months Ended

Jun. 30, 2018

T hree Months Ended June 30, 2018	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	6,665		$	—		$	—		$	6,665
License revenue		257,709			—			—			257,709
Grant and other revenue		156,889			120,864			—			277,753
Total revenue		421,263			120,864			—			542,127
Cost of revenue		35,392			—			—			35,392
Research and development expenses		913,158			229,560			—			1,142,718
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			16,630			1,735,258			1,751,888
Depreciation and amortization (2)		—			—			37,511			37,511
Loss from operations (3)		(527,287	)		(125,326	)		(1,772,769	)		(2,425,382	)
Other expense (4)		—			—			(20,719	)		(20,719	)
Income tax benefit		2,356			560			8,013			10,929
Net loss from continuing operations		(524,931	)		(124,766	)		(1,785,475	)		(2,435,172	)
Loss from discontinued operations, net of tax		(1,938	)		—			—			(1,938	)
Gain on sale of discontinued operations, net of tax		43,053			—			—			43,053
Net loss		(483,816	)		(124,766	)		(1,785,475	)		(2,394,057	)
Total assets, net of depreciation and amortization:
United States	$	409,769		$	87,751		$	8,139,434		$	8,636,954
International		22,147			—			1,391			23,538
Capital expenditures		—			—			3,165			3,165

T hree Months Ended June 30, 2017	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	—		$	—		$	—		$	—
License revenue		100,000			—			—			100,000
Grant and other revenue		418,375			93,224			—			511,599
Total revenue		518,375			93,224			—			611,599
Research and development expenses		1,108,101			77,773			—			1,185,874
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			3,462			4,175,583			4,179,045
Depreciation and amortization (2)		—			—			70,539			70,539
(Loss) income from operations (3)		(589,726	)		11,989			(4,246,122	)		(4,823,859	)
Other income		—			—			40,848			40,848
Income tax benefit (expense)		201,125			(4,089	)		1,434,198			1,631,234
Net (loss) income from continuing operations		(388,601	)		7,900			(2,771,076	)		(3,151,777	)
Loss from discontinued operations, net of tax		(82,376	)		—			—			(82,376	)
Loss on sale of discontinued operations, net of tax		(1,953,378	)		—			—			(1,953,378	)
Net (loss) income		(2,424,355	)		7,900			(2,771,076	)		(5,187,531	)
Total assets, net of depreciation and amortization:
United States	$	16,373,919		$	16,002		$	9,411,189		$	25,801,110
International		98,806			—			2,299			101,105
Capital expenditures		—			—			8,170			8,170

Six Months Ended June 30, 2018	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	7,460		$	—		$	—		$	7,460
License revenue		257,709			—			—			257,709
Grant and other revenue		389,325			164,078			—			553,403
Total revenue		654,494			164,078			—			818,572
Cost of revenue		35,710			—			—			35,710
Research and development expenses		1,698,169			443,505			—			2,141,674
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			25,237			3,465,036			3,490,273
Depreciation and amortization (2)		—			—			75,498			75,498
Loss from operations (3)		(1,079,385	)		(304,664	)		(3,540,534	)		(4,924,583	)
Other expense (4)		—			—			(4,259,480	)		(4,259,480	)
Income tax benefit		1,284			363			9,282			10,929
Net loss from continuing operations		(1,078,101	)		(304,301	)		(7,790,732	)		(9,173,134	)
Loss from discontinued operations, net of tax		(1,938	)		—			—			(1,938	)
Gain on sale of discontinued operations, net of tax		43,053			—			—			43,053
Net loss		(1,036,986	)		(304,301	)		(7,790,732	)		(9,132,019	)
Total assets, net of depreciation and amortization:
United States	$	409,769		$	87,751		$	8,139,434		$	8,636,954
International		22,147			—			1,391			23,538
Capital expenditures		—			—			3,165			3,165

Six Months Ended June 30, 2017	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	—		$	—		$	—		$	—
License revenue		100,000			—			—			100,000
Grant and other revenue		989,737			101,892			—			1,091,629
Total revenue		1,089,737			101,892			—			1,191,629
Cost of revenue		—			—			—			—
Research and development expenses		1,521,303			369,845			—			1,891,148
Selling, general and administrative expenses, excluding depreciation and amortization (1)		—			5,983			7,118,706			7,124,689
Depreciation and amortization (2)		—			—			147,329			147,329
Loss from operations (3)		(431,566	)		(273,936	)		(7,266,035	)		(7,971,537	)
Other expense (4)		—			—			(1,130,261	)		(1,130,261	)
Income tax benefit		146,296			92,861			2,846,249			3,085,406
Net loss from continuing operations		(285,270	)		(181,075	)		(5,550,047	)		(6,016,392	)
Loss from discontinued operations, net of tax		(338,237	)		—			—			(338,237	)
Gain on sale of discontinued operations, net of tax		86,748,123			—			—			86,748,123
Net income (loss)		86,124,616			(181,075	)		(5,550,047	)		80,393,494
Total assets, net of depreciation and amortization:
United States	$	16,373,919		$	16,002		$	9,411,189		$	25,801,110
International		98,806			—			2,299			101,105
Capital expenditures		—			—			8,170			8,170